Katsuwonus pelamis Peptide and its Complexes Protect Zebrafish and Mice From Hyperuricemia Through Promoting Kidney Excretion of Uric Acid and Inhibiting Liver Xanthine Oxidase Activity

Abstract

Katsuwonus pelamispeptide and its complexes have the effect of lowering uric acid (UA)-levels. To identify the effect and possible mechanisms, different concentrations ofKatsuwonus pelamispeptide and its complexes were administered to the zebrafish and mice hyperuricemia models, and the UA level was measured. Meanwhile, the hyperuricemic mice were treated orally at 0.83, 1.67, and 5.00 mg/g body weight for 7 days withKatsuwonus pelamispeptide and the complexes groups, separately. The levels of serum UA (SUA), urinary UA (UUA), serum creatinine (SCR), blood urine nitrogen (BUN), and xanthine oxidase (XOD) activities were detected in each group. The results showed that theKatsuwonus pelamispeptide (125 μg/ml) and its complexes (83.3 and 250 μg/ml) effectively reduced UA level in zebrafish with hyperuricemia (p< 0.05). TheKatsuwonus pelamispeptide at high concentration (5.00 mg/g) decreased the SUA level, SCR level, BUN level, and hepatic XOD activity, and the complexes (1.67 and 5.00 mg/g) significantly reduced the SUA level and hepatic XOD activity (p< 0.05) in the hyperuricemic mice. In addition, in a hyperuricemic mouse model, the UUA level was increased after treatment withKatsuwonus pelamispeptide and its complexes at high concentrations (p< 0.05). The total therapeutic effects in theKatsuwonus pelamispeptide complex group were better than those in theKatsuwonus pelamispeptide group. Thus,Katsuwonus pelamispeptide and its complexes may possibly be used to prevent hyperuricemiaviapromoting urate secretion and inhibiting XOD activity production.